The panel of experts voted 10-5 to back the Celgene drug Revlimid for patients with myelodysplastic syndromes, based on Phase II studies of patients with MDS who have a certain genetic abnormality. The majority of those voting against approval said they wanted to wait for data from a Phase III study now beginning to enroll patients.

Related Summaries